CN120435496A - 调节巨噬细胞活性的组合物和方法 - Google Patents

调节巨噬细胞活性的组合物和方法

Info

Publication number
CN120435496A
CN120435496A CN202380079852.1A CN202380079852A CN120435496A CN 120435496 A CN120435496 A CN 120435496A CN 202380079852 A CN202380079852 A CN 202380079852A CN 120435496 A CN120435496 A CN 120435496A
Authority
CN
China
Prior art keywords
human
seq
lilrb1
antibody
lilrb2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380079852.1A
Other languages
English (en)
Chinese (zh)
Inventor
卢卡·卡塞塔
斯蒂芬·迈亚特
卡罗拉·里斯
克里斯托弗·B·维歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mccormick Ltd
Original Assignee
Mccormick Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mccormick Ltd filed Critical Mccormick Ltd
Priority claimed from PCT/GB2023/050592 external-priority patent/WO2023170434A1/en
Publication of CN120435496A publication Critical patent/CN120435496A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380079852.1A 2022-10-04 2023-03-13 调节巨噬细胞活性的组合物和方法 Pending CN120435496A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2214614.6A GB202214614D0 (en) 2022-10-04 2022-10-04 Compositions and methods for modulation of macrophage
GB2214614.6 2022-10-04
PCT/GB2023/050592 WO2023170434A1 (en) 2022-03-11 2023-03-13 Compositions and methods for modulation of macrophage activity

Publications (1)

Publication Number Publication Date
CN120435496A true CN120435496A (zh) 2025-08-05

Family

ID=84000149

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380079852.1A Pending CN120435496A (zh) 2022-10-04 2023-03-13 调节巨噬细胞活性的组合物和方法

Country Status (8)

Country Link
JP (1) JP2025535192A (https=)
KR (1) KR20250096720A (https=)
CN (1) CN120435496A (https=)
AU (1) AU2023232991A1 (https=)
CR (1) CR20250172A (https=)
GB (1) GB202214614D0 (https=)
IL (1) IL319958A (https=)
MX (1) MX2025003929A (https=)

Also Published As

Publication number Publication date
JP2025535192A (ja) 2025-10-22
MX2025003929A (es) 2025-05-02
CR20250172A (es) 2025-09-04
IL319958A (en) 2025-05-01
AU2023232991A1 (en) 2025-04-10
KR20250096720A (ko) 2025-06-27
GB202214614D0 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
JP7765397B2 (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
US12077585B2 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
JP6405242B2 (ja) Ｍｉｃａ結合剤
JP2022068161A (ja) 新規抗ｐｄ－ｌ１抗体
WO2019179391A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
CN113194994B (zh) 使用抗trem2抗体的方法
JP7022067B2 (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
US20250197491A1 (en) Compositions and methods for modulation of macrophage activity
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
US20240360229A1 (en) Multispecific antibodies and uses thereof
US20250171534A1 (en) Anti-lilrb1/2 antibodies and uses thereof
CN115087672A (zh) 抗人hvem(tnfrsf14)抗体及其用途
US20230272056A1 (en) Affinity matured anti-lap antibodies and uses thereof
CN113748132B (zh) 抗trem1抗体和相关方法
CN120435496A (zh) 调节巨噬细胞活性的组合物和方法
CN118852427A (zh) 靶向cd70的单克隆抗体及其用途
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN117715940A (zh) 抗trem-1抗体
CN116710482A (zh) 特异性结合4-1bb的抗体及其抗原结合片段
US20250325643A1 (en) Binding agents capable of binding to cd27 in combination therapy
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
EP4522657A1 (en) Binding agents capable of binding to cd27 in combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination